Quick Answer
SAB Biotherapeutics, Inc. reported Stockholders Equity of $151.49 million for the year ending 2025.
- SAB Biotherapeutics, Inc. showed an increase of +483.4% in Stockholders Equity from 2024 to 2025.
- This data is from SAB Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2019 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $40.77 million | Q2 2021: $38.26 million | Q3 2021: $35.08 million | Q1 2022: $41.26 million | Q2 2022: $37.12 million | Q3 2022: $30.62 million | Q1 2023: $24.40 million | Q2 2023: $19.72 million | Q3 2023: $15.26 million | Q1 2024: $52.82 million | Q2 2024: $46.12 million | Q3 2024: $36.90 million | Q1 2025: $21.41 million | Q2 2025: $12.02 million | Q3 2025: $165.07 million.
- Over the full 9 years of available data (2019 to 2025), SAB Biotherapeutics, Inc.'s Stockholders Equity has grown by 1,868.9%.
- Historical annual values: Fiscal year 2025: $151.49 million | Fiscal year 2024: $25.97 million | Fiscal year 2023: $57.30 million | Fiscal year 2022: $31.06 million | Fiscal year 2022: $37.12 million | Fiscal year 2022: $41.26 million | Fiscal year 2021: $38.55 million | Fiscal year 2020: $39.01 million | Fiscal year 2019: $7.69 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: